Insider Transactions in Q1 2021 at Allogene Therapeutics, Inc. (ALLO)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 26
2021
|
Rafael Amado EVP of R&D |
BUY
Grant, award, or other acquisition
|
Direct |
24,866
+15.56%
|
-
|
|
Mar 26
2021
|
Eric Thomas Schmidt Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,866
+20.56%
|
-
|
|
Mar 26
2021
|
Alison Moore Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,866
+16.33%
|
-
|
|
Mar 26
2021
|
Veer Bhavnagri General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
22,202
+5.01%
|
-
|
|
Mar 26
2021
|
David D Chang President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
80,452
+3.4%
|
-
|
|
Mar 26
2021
|
Arie Belldegrun Director |
BUY
Grant, award, or other acquisition
|
Direct |
53,635
+20.82%
|
-
|
|
Mar 15
2021
|
Eric Thomas Schmidt Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
8,053
-10.16%
|
$306,014
$38.23 P/Share
|
|
Mar 15
2021
|
Veer Bhavnagri General Counsel |
SELL
Open market or private sale
|
Direct |
16,623
-1.35%
|
$631,674
$38.03 P/Share
|
|
Mar 15
2021
|
Veer Bhavnagri General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+2.35%
|
$20,000
$2.27 P/Share
|
|
Mar 15
2021
|
Alison Moore Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
6,164
-5.67%
|
$234,232
$38.14 P/Share
|
|
Mar 15
2021
|
David D Chang President and CEO |
SELL
Open market or private sale
|
Direct |
20,513
-0.92%
|
$779,494
$38.57 P/Share
|
|
Mar 15
2021
|
Rafael Amado EVP of R&D |
SELL
Open market or private sale
|
Direct |
2,798
-2.48%
|
$106,324
$38.05 P/Share
|
|
Jan 15
2021
|
Eric Thomas Schmidt Chief Financial Officer |
SELL
Open market or private sale
|
Indirect |
15,000
-0.43%
|
$480,000
$32.46 P/Share
|
|
Jan 14
2021
|
Eric Thomas Schmidt Chief Financial Officer |
SELL
Open market or private sale
|
Indirect |
15,000
-0.64%
|
$450,000
$30.85 P/Share
|